ライフサイエンスコーパス: intratumor

1 is study was to compare visual assessment of intratumor (18)F-FDG PET uptake distribution with a text

2 Results: Intratumor (18)F-FGln uptake patterns demonstrated subst

3 etention in tumors through regulation of the intratumor abundance of CCL21.

4 -0111 and injection of gemcitabine increased intratumor acidosis and increased cell death.

5 We hypothesize that intratumor adenosine impairs the ability of lymphokine-a

6 It involves an intratumor administration of a laser-absorbing dye and a

7 In contrast, intratumor administration of an Ad vector to individuals

8 ed murine mammary tumors (4T1) in vivo after intratumor administration.

9 in mice for toxicity and DNA delivery after intratumor and i.m. injection.

10 technologies have revealed the prevalence of intratumor and intertumor heterogeneity.

11 subtypes, and patients to fully characterize intratumor and intertumor molecular heterogeneity.

12 production of IL17, which promotes influx of intratumor B cells that promote tumor growth and progres

13 The intratumor bacteria are mostly intracellular and are pre

14 nocarcinoma (PDAC), and we hypothesized that intratumor bacteria might contribute to drug resistance

15 We also noted correlations between intratumor bacteria or their predicted functions with tu

16 er infiltration and a striking change in the intratumor balance of Tregs and Teffs that directly corr

17 To model its in vivo role in the intratumor biomechanical environment, we investigated wh

18 The intratumor bleeding and tumor growth arrest could be rev

19 ualization of capillaries, a high density of intratumor blood vessels was visualized in CPC mice.

20 treated with KLAK-MCP1 demonstrated reduced intratumor CCR2 expression and altered infiltration of T

21 A decreased influx of intratumor CD8(+) T cells was also observed.

22 the efficacy of anti-PD1 mAb and function of intratumor CD8(+) T cells.

23 analyses provide a framework to interrogate intratumor CD8(+) T-cell PD1 and immune PDL1 levels and

24 LUAD(non-muc), LUAD(Muc) cases showed lower intratumor CD8(+), PD-1(+), CD8(+)PD-1(+), and FOXP3(+)

25 C57BL6 mice reduced tumor size and increased intratumor CD8+ T cell infiltration, that formed synapse

26 In the absence of ACKR4, an increase in intratumor CD8+ T cells inhibited tumor growth, and nonh

27 Intratumor cell heterogeneity can therefore be maintaine

28 Intratumor cellular heterogeneity and non-genetic cell p

29 Intratumor clones typically showed less diversity in met

30 mRNA profiles were highly similar in all 59 intratumor comparisons, in distinct contrast to the mark

31 ts triggered release under intracellular and intratumor conditions.

32 tanercept-treated WT mice displayed enhanced intratumor content of high endothelial venules surrounde

33 ht be enhanced by pharmacologically reducing intratumor copper levels.

34 In addition, we investigated intratumor copy number of PDJ amplicons in PDJ+ and PDJ-

35 ntiation of antitumor Th17 cells that induce intratumor CTL recruitment and subsequent regression of

36 anti-HER2 antibodies, demonstrated increased intratumor CUL5 expression, decreased surface HER2, and

37 We found that combined systemic IL-2 with an intratumor CXCR3 ligand (CXCL9) lead to significantly gr

38 the combined strategy of systemic IL-2 with intratumor CXCR3 ligand is more efficacious than either

39 mononuclear cells followed by enhancing the intratumor CXCR3 ligand levels to establish optimal CXCR

40 FACS analysis of the intratumor DCs showed that they were predominantly immat

41 Additionally, intratumor delivery of CCL5 mRNA using lipid nanoparticl

42 5, we created an adenovirus-based vector for intratumor delivery, named Mobilan that drives expressio

43 Therefore, intratumor delta-catenin heterogeneity originated from g

44 studies have reported a correlation between intratumor dihydropyrimidine dehydrogenase (DPD) messeng

45 Cy5-RO5323441 was injected to study the intratumor distribution of RO5323441 with fluorescence m

46 iological features of tumors and control the intratumor distribution of these drug carriers should im

47 1P was cleared from the blood, reflecting an intratumor distribution process of SS1P that is independ

48 Intratumor distribution was assessed by fluorescence mic

49 mes in tumor vessels, suggesting a change in intratumor distribution; no significant effect of charge

50 KB cell xenografts (10-100 mg), whereas the intratumor distributions were investigated by autoradiog

51 The prevailing model for explaining intratumor diversity, the clonal evolution model, has re

52 what was predicted based on the increase in intratumor Doxil concentration.

53 emphasizing the need to directly measure the intratumor drug concentration.

54 d be a useful imaging tool for measuring the intratumor drug distribution.

55 8)F-FCP PET, we could image and identify the intratumor drug profile.

56 measurements also showed the non-homogeneous intratumor electric potentials.

57 Intratumor enrichment of eATP promotes the monocyte infi

58 Intratumor epigenetic heterogeneity is emerging as a key

59 In cases where intratumor/episcleral plaque edema or hemorrhage shifted

60 le system for genetic induction of permanent intratumor expression of KDM5B and screened for chemical

61 poorly fibrogenic, some tumors harbor focal intratumor extracellular matrix (ECM) deposits called "f

62 is behavior was traced to an aberrantly high intratumor FABP5/CRABP-II ratio.

63 mutated colorectal cancer patients with low intratumor ferritin mRNA levels display longer 3- and 5-

64 Hence, histologic reporting of intratumor fibrosis in HCC is of clinical relevance.

65 therapy response, with resolution to reveal intratumor functional cancer heterogeneity.

66 model, gemcitabine resistance was induced by intratumor Gammaproteobacteria, dependent on bacterial C

67 been suggested as an ideal means of sampling intratumor genetic and epigenetic heterogeneity for diag

68 neration sequencing allows the assessment of intratumor genetic heterogeneity (ITGH), a phenomenon th

69 ting such complexity, increasing evidence of intratumor genetic heterogeneity (ITH) is emerging, both

70 African Americans had greater intratumor genetic heterogeneity and more basal gene exp

71 revealed that ductal carcinomas in situ show intratumor genetic heterogeneity at diagnosis and that t

72 Thirteen primary tumor foci exhibited intratumor genetic heterogeneity by FISH.

73 However, the extraordinary intratumor genetic heterogeneity in cancers revealed by

74 and triple-negative tumor prevalence but not intratumor genetic heterogeneity influenced the magnitud

75 Intratumor genetic heterogeneity is a key mechanism unde

76 This intratumor genetic heterogeneity poses a substantial cha

77 Intratumor genetic heterogeneity reflects the evolutiona

78 Intratumor genetic heterogeneity underlies the ability o

79 Intratumor genetic heterogeneity was greater in African

80 Intratumor genetic heterogeneity, which occurs in additi

81 asis through continuous prevention of severe intratumor hemorrhage and consequent cell death.

82 This suggests that the prevention of intratumor hemorrhage by platelets relies on the secreti

83 SL-DOX, MR imaging revealed the induction of intratumor hemorrhage in 63-75% of rats (n = 8).

84 rapid destabilization of tumor vessels with intratumor hemorrhage starting as soon as 30 min after i

85 platelet integrin activation did not lead to intratumor hemorrhage.

86 esting and degranulated platelets to prevent intratumor hemorrhage.

87 of putative drivers that underlie inter- and intratumor heterogeneities in CLL affecting disease prog

88 on bulk 'omic' data, which fails to capture intratumor heterogeneity (ITH) and deconvolve signals fr

89 Intratumor heterogeneity (ITH) and tumor evolution have

90 Intratumor heterogeneity (ITH) drives neoplastic progres

91 n Cell by Wolf et al. demonstrates that high intratumor heterogeneity (ITH) for cancer neoantigens pa

92 Intratumor heterogeneity (ITH) is a driver of tumor evol

93 Intratumor heterogeneity (ITH) of genomic alterations ma

94 A consequence of the intratumor heterogeneity (ITH) of glioblastoma (GBM) is

95 Herein, we explored the genomic origin and intratumor heterogeneity (ITH) of PSC.

96 We explored the impact of neoantigen intratumor heterogeneity (ITH) on antitumor immunity.

97 Here we report an unanticipated impact of intratumor heterogeneity (ITH) on risk prediction of rec

98 r selective growth advantages, contribute to intratumor heterogeneity (ITH), and accelerate tumor evo

99 High intratumor heterogeneity (ITH), where the majority of Ne

100 and phenotypic features, a phenomenon termed intratumor heterogeneity (ITH).

101 r cell renal carcinomas (ccRCCs) can display intratumor heterogeneity (ITH).

102 lonal evolution, leading to a high degree of intratumor heterogeneity (ITH).

103 Transcriptomic intratumor heterogeneity (RNA-ITH) has been shown to con

104 Our results show varying degrees of intratumor heterogeneity among patients.

105 In this review, we discuss the sources of intratumor heterogeneity and approaches to capture and a

106 non-small-cell lung cancer (NSCLC), data on intratumor heterogeneity and cancer genome evolution hav

107 in anti-tumor immunity and demonstrate that intratumor heterogeneity and clonal cooperation can cont

108 l approaches that are commonly used to infer intratumor heterogeneity and describe how these methodol

109 RNA sequencing (scRNA-seq) are used to study intratumor heterogeneity and detect clonal groups, a sof

110 r relapse and a thorough characterization of intratumor heterogeneity and disease-resistant cell popu

111 ntext of tumor evolution and their impact on intratumor heterogeneity and drug development.

112 ew discusses the sources and consequences of intratumor heterogeneity and how these are recapitulated

113 ancer drug development is challenged by high intratumor heterogeneity and interpatient diversity.

114 ntributes to a mathematical understanding of intratumor heterogeneity and is also applicable to organ

115 The discovery of extensive intratumor heterogeneity and ongoing clonal adaptation i

116 ce is the direct consequence of pre-existing intratumor heterogeneity and ongoing diversification dur

117 mage features that allowed quantification of intratumor heterogeneity and peak standardized uptake va

118 events, and assess the relationship between intratumor heterogeneity and recurrence-free survival.

119 communicate at long range in vivo, inducing intratumor heterogeneity and resistance to treatment.

120 chromosomal instability were associated with intratumor heterogeneity and resulted in parallel evolut

121 light the importance of genetic diversity in intratumor heterogeneity and the value of analyzing tumo

122 ir origin, structural dynamics and impact on intratumor heterogeneity are still unresolved.

123 Intratumor heterogeneity as a clinical challenge becomes

124 However, the extent of intratumor heterogeneity as a result of tumor evolution

125 Intratumor heterogeneity associates with poor patient ou

126 We have explored intratumor heterogeneity at the epigenetic level, due to

127 However, investigators are now elucidating intratumor heterogeneity at the single-cell level due to

128 urBayes, to estimate tumor purity and detect intratumor heterogeneity based on next-generation sequen

129 Intratumor heterogeneity can lead to underestimation of

130 Tumor complexity and intratumor heterogeneity contribute to subclonal diversi

131 ummarize important considerations related to intratumor heterogeneity during tumor evolution.

132 Intratumor heterogeneity establishes early, as in AIS.

133 ion significantly affected quantification of intratumor heterogeneity for all textural parameters (P

134 We observed widespread intratumor heterogeneity for both somatic copy-number al

135 hybridization technique revealed inter- and intratumor heterogeneity for expression of the metastasi

136 mor were analyzed independently, we detected intratumor heterogeneity for PIK3CA mutations.

137 a plausible mechanism for predetermining the intratumor heterogeneity found in colon cancers.

138 ad utility of EVA to quantify intertumor and intratumor heterogeneity from scRNA-seq data without rel

139 gnosis most tumors show a striking amount of intratumor heterogeneity in all measurable phenotypes; s

140 Intratumor heterogeneity in biologic properties and in r

141 However, some intratumor heterogeneity in chromosome content was found

142 There was pronounced intratumor heterogeneity in copy number alterations, tra

143 s, a fraction of genes exhibited significant intratumor heterogeneity in expression.

144 Our approach can generate reliable maps of intratumor heterogeneity in large numbers of patients wi

145 We hypothesized that investigating intratumor heterogeneity in meningiomas would elucidate

146 , G4 landscapes reveal additional IC-related intratumor heterogeneity in PDTX biopsies, improving bre

147 We wanted to prospectively investigate intratumor heterogeneity in relation to clinical outcome

148 Inter- and intratumor heterogeneity in signaling within various tum

149 of ability to fully recapitulate inter- and intratumor heterogeneity in vitro and of availability of

150 Intratumor heterogeneity is a key hallmark of cancer tha

151 Intratumor heterogeneity is a major clinical problem bec

152 Another relevant aspect in intratumor heterogeneity is cell plasticity-the ability

153 Thus, intratumor heterogeneity is like an arsenal, providing a

154 understanding of the extent and evolution of intratumor heterogeneity is therefore of direct clinical

155 Accumulating evidence suggests that intratumor heterogeneity likely is the key to understand

156 Measurements of intratumor heterogeneity may also be used as biomarkers

157 Intratumor heterogeneity may foster tumor evolution and

158 time in culture and that varying degrees of intratumor heterogeneity may originate from individually

159 Intratumor heterogeneity mediated through chromosome ins

160 single-cell RNA sequencing demonstrated that intratumor heterogeneity necessitates the combination of

161 Intratumor heterogeneity of 3p12.2, 6p21.2, and 8q11.23

162 Conversely, intratumor heterogeneity of chromosomal anomalies was id

163 umerous cancer types exhibit high inter- and intratumor heterogeneity of H1.0, with H1.0 levels corre

164 pment and may be informed by the presence of intratumor heterogeneity of KRAS and NRAS mutations.

165 solution and depth information to reveal the intratumor heterogeneity of mAb-IR700 distribution.

166 The inter- and intratumor heterogeneity of PDXs, however, presents seve

167 Here we report that intratumor heterogeneity of Wnt/beta-catenin modulator d

168 rovide a framework to decipher the impact of intratumor heterogeneity on key cancer phenotypes, and t

169 To better understand the implications of intratumor heterogeneity on therapeutic outcomes, we cre

170 nd enable high-depth sequencing required for intratumor heterogeneity profiling.

171 Intratumor heterogeneity remains a major obstacle to eff

172 Intratumor heterogeneity represents a major obstacle to

173 The extensive intratumor heterogeneity revealed by sequencing cancer g

174 This disease is uniformly fatal, with intratumor heterogeneity the major reason for treatment

175 The early cancer-immune interaction sculpts intratumor heterogeneity through the selection of immune

176 biochemical and cellular mechanisms linking intratumor heterogeneity to the molecular, temporal and

177 que especially well suited to characterizing intratumor heterogeneity using counts of probes to genet

178 We characterized the consequences of intratumor heterogeneity using immunohistochemical analy

179 Accurate measurement of intratumor heterogeneity using parameters of texture on

180 tory gating and image noise on assessment of intratumor heterogeneity was evaluated using Cox regress

181 Intratumor heterogeneity was observed for a mutation wit

182 Substantial inter- and intratumor heterogeneity was observed for all investigat

183 Mutational intratumor heterogeneity was seen for multiple tumor-sup

184 The degree of intratumor heterogeneity was significantly higher in ane

185 Intratumor heterogeneity was visually scored (3-level sc

186 S-TP53 co-altered PDAC reveals conflation of intratumor heterogeneity with progenitor-like stemness p

187 Our data also demonstrate extensive intratumor heterogeneity with respect to c-MYC copy numb

188 on, the adenoma and cancer further developed intratumor heterogeneity with the accumulation of nonran

189 icancer therapies vary due to intertumor and intratumor heterogeneity(1).

190 ere, we investigate the additional impact of intratumor heterogeneity, a largely unstudied component

191 Intratumor heterogeneity, although present at the level

192 ility (CIN) contributes to cancer evolution, intratumor heterogeneity, and drug resistance.

193 y contribute to maintenance of GSCs, promote intratumor heterogeneity, and potentially provide innova

194 results present a single-cell atlas, explore intratumor heterogeneity, and provide potential therapeu

195 of differentiating tumor types, visualizing intratumor heterogeneity, and segmenting anatomical stru

196 Intratumor heterogeneity, associated with heterogeneous

197 n was associated with an increase of ploidy, intratumor heterogeneity, copy-number alteration, altere

198 eq is now ubiquitously adopted in studies of intratumor heterogeneity, detection of somatic mutations

199 ally implementable pathologic definitions of intratumor heterogeneity, genetic diversity, and chromos

200 Different mechanisms contribute to intratumor heterogeneity, including genetic mutations, t

201 ppreciation for the extent and importance of intratumor heterogeneity, much attention in cancer resea

202 opy number alterations, mutation signatures, intratumor heterogeneity, pathway alterations, histology

203 N) is a driver of clonal diversification and intratumor heterogeneity, providing genetic diversity th

204 r research and improved our understanding of intratumor heterogeneity, the tumor microenvironment, me

205 elevant genetic alterations that manifest as intratumor heterogeneity, these aggregate analyses may m

206 s, and the appearance of naturally occurring intratumor heterogeneity, thus recapitulating the stocha

207 To examine intratumor heterogeneity, we performed exome sequencing,

208 Intratumor heterogeneity, which fosters tumor evolution,

209 ploidy profiling analysis revealed extensive intratumor heterogeneity, with 26 of 30 tumor samples fr

210 ted genomic analysis that uncovers extensive intratumor heterogeneity, with most patients displaying

211 mary brain tumors known for their inter- and intratumor heterogeneity.

212 emonstrated the ability to uncover molecular intratumor heterogeneity.

213 t is able to better resolve the biomolecular intratumor heterogeneity.

214 of different diseases with broad inter- and intratumor heterogeneity.

215 en its potential advantage in the setting of intratumor heterogeneity.

216 e therapeutic outcomes by directly targeting intratumor heterogeneity.

217 nd DNA analysis, and revealed no significant intratumor heterogeneity.

218 l level and is used to assess intertumor and intratumor heterogeneity.

219 ssue, with treatment challenges arising from intratumor heterogeneity.

220 DCs often suffer from issues associated with intratumor heterogeneity.

221 ionales to overcome malignant plasticity and intratumor heterogeneity.

222 d to faster cell mixing and lower observable intratumor heterogeneity.

223 ppressors may provide a potent way to defeat intratumor heterogeneity.

224 Surface markers that displayed intratumor heterogeneous expression among epithelial can

225 In particular, intratumor human cluster of differentiation-positive (hC

226 refilling of a delivery depot consisting of intratumor hydrogels completely abrogated tumor growth.

227 risingly, although there was no induction of intratumor hypoxia by anti-Sema4D therapy, the increase

228 uced by angiogenesis inhibitors is increased intratumor hypoxia.

229 protein 1, which up-regulated IL-6 in other intratumor immune cells and activated the JAK2/STAT3 pat

230 Relief of intratumor immunosuppression may increase considerably t

231 sis, increased tumor necrosis, and increased intratumor infiltration of CXCR3+ mononuclear cells, as

232 Moreover, treatment by direct intratumor injection into subcutaneous solid tumors of B

233 dy, we evaluated the effects of intermittent intratumor injection of a nonselective adenosine recepto

234 d potent systemic antitumor activities after intratumor injection of Ad-HT.

235 administration of IL-12 in combination with intratumor injection of anti-HLA-I antibody significantl

236 The data show that intratumor injection of CpG-oligodeoxynucleotides is a p

237 Intratumor injection of CpG-oligodeoxynucleotides was sh

238 Furthermore, intratumor injection of DNA-liposome complex containing

239 Intratumor injection of human CD24 and Her2/neu-specific

240 expression of costimulatory molecules or by intratumor injection of naive T cells.

241 Intratumor injection of the Ad5IL-12 vector to establish

242 tive expansion of the higher-avidity CTL and intratumor injection of the peptide may enhance the effe

243 CD8+ T-cell responses were induced by Ad-HT intratumor injection.

244 median age, 64 years) received a total of 83 intratumor injections with Adp53.

245 ere indistinguishable from those produced by intratumor inoculations of Burkitt's tumors with IP-10.

246 Reconstitution of intratumor IP-10 for a period of 8 wk resulted in a sign

247 IFN-gamma enzyme-linked immunospot assay and intratumor (IT) and circulating immune phenotypes (CD4 +

248 The elevated intratumor levels of adenosine might inhibit the antitum

249 therapeutic effects during PIT at different intratumor locations (e.g., tumor surface vs. deep tumor

250 stasizing cancer cells reach lymph nodes via intratumor lymphatic vessels is unknown.

251 The absence of intratumor lymphatics in hepatocellular carcinomas and l

252 neck, we apply this algorithm to define the intratumor metabolic landscape.

253 The intratumor microenvironment generates phenotypically dis

254 abundance (P < 0.05) of edge-associated and intratumor microvessels, but not of stromally located mi

255 d a microdevice platform to recapitulate the intratumor oxygen gradients that drive the heterogeneous

256 In addition to spatial patterns of intratumor paracrine signaling, a possible cell-cycle-as

257 -PD1 therapy and remain dysfunctional unless intratumor PDL1(lo) immune cells are targeted.

258 ti-CD137 mAb treatment resulted in prolonged intratumor persistence of the OT1 CTL-effector cells and

259 on of COX-2 by celecoxib resulted in loss of intratumor PGE2 levels and reduced tumor growth in a dos

260 Intratumor phenotypic and functional heterogeneity have

261 nvironment and cancer cell plasticity drives intratumor phenotypic heterogeneity and underpins diseas

262 f antimelanoma specific T cells suggest that intratumor-produced adenosine could impair the function

263 lls to infiltrate the tumor and increase the intratumor ratio of effector T cell/T reg cell.

264 n the tumor, highlight the importance of the intratumor ratio of effectors to regulators, and demonst

265 ytic signal amplification of ROS, furnishing intratumor redox photomodulation for therapy.

266 In contrast, intratumor regions had only zero to four gene changes at

267 ars to be adequate for the identification of intratumor regions of hypoxia.

268 e size of ROI(peak) caused more variation in intratumor response than did the location or shape of RO

269 -cells locally deliver GD2.BiCE and increase intratumor retention of NK-cells.

270 Intratumor spatial heterogeneity facilitates therapeutic

271 colonic axis or in the relative quantity of intratumor stromal myofibroblasts as marked by the expre

272 Here we perform immunogenomic analyses on 67 intratumor sub-regions of a PD-1 inhibitor-resistant mel

273 The differential intratumor subcellular localization of delta-catenin mir

274 While it is well-established that intratumor, subclonal genetic and phenotypic heterogenei

275 esis patterns distinguishing region-specific intratumor subpopulations.

276 )F-FDG PET/CT have been reported to identify intratumor subvolumes at high risk of relapse after radi

277 above to 46% below the mean (CV, 17%) and an intratumor SUV(peak) response variation ranging from 49%

278 The variable ROI(peak) definition led to an intratumor SUV(peak) variation ranging from 49% above to

279 chemokine receptor 4 (ACKR4) in controlling intratumor T cell accumulation and activation.

280 this limitation by using flow-sorted HRS and intratumor T cells and optimized low-input exome sequenc

281 lear factor kappaB pathway and a decrease in intratumor T-cell infiltration.

282 also demonstrated strong efficacy, enhancing intratumor T-cell number, activation, and reduced exhaus

283 the composition and spatial organization of intratumor T-cell populations is prognostic in some canc

284 gefitinib on topotecan tECF penetration and intratumor topotecan distribution.

285 images were rigidly registered together, and intratumor tracer uptake distributions were compared.

286 Intratumor transgene mRNA was identified in 43% of asses

287 Intratumor Tregs are partly responsible for the developm

288 g penetration in tumors, associated with the intratumor upregulation of leukocyte-endothelial cell ad

289 glycolysis, and, more recently, the proposed intratumor uptake heterogeneity features.

290 The results of this study demonstrate that intratumor vaccination with a recombinant oncolytic aden

291 has been identified, in detail, a group with intratumor values of relative cerebral blood volume (rCB

292 sults reveal the genome-wide architecture of intratumor variability in GB across multiple spatial sca

293 atterns of gene expression demonstrated that intratumor variation was substantially less than the tot

294 ice significantly reduced immunosuppression, intratumor vascularization, and local and metastatic bre

295 In B16 melanoma model, intratumor VBL injection induced apoptosis of melanoma c

296 noma was markedly reduced in C57BL/6 mice by intratumor VBL injection.

297 n in endothelial cells in edge-associated or intratumor vessels using this model might reveal mechani

298 The investigation of intratumor voxel doses indicates that mean tumor dose is

299 Intratumor voxels were classified into 4 clusters based

300 Intratumor voxels were stratified as being increased (PR